G1 THERAPEUTICS INC (GTHX)       12.8  +0.39 (+3.14%)

12.8  +0.39 (+3.14%)

US3621LQ1099 - Common Stock - After market: 12.5 -0.3 (-2.34%)

G1 THERAPEUTICS INC12.8

NASDAQ:GTHX (10/4/2022, 7:00:02 PM)+0.39 (+3.14%)

After market: 12.5 -0.3 (-2.34%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 08-03 2022-08-03/bmo Earnings (Next) 11-01 2022-11-01
Ins Owners 1.81% Inst Owners 45.85%
Market Cap 547.16M Shares 42.75M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 81.43
IPO 05-17 2017-05-17

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

GTHX Daily chart

Company Profile

G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. The company is headquartered in Research Triangle Park, North Carolina and currently employs 148 full-time employees. The company went IPO on 2017-05-17. The firm is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The firm's lead compound COSELA (trilaciclib), is a therapy designed to help protect hematopoietic stem and progenitor cells (HSPCs) in bone marrow against chemotherapy-induced myelosuppression by transiently inhibiting CDK4/6 in patients with extensive-stage small cell lunger cancer (ES-SCLC). Its Lerociclib, is a differentiated clinical-stage oral CDK4/6 inhibitor for use in combination with other targeted therapies in multiple oncology indications. The firm's Rintodestrant, is a clinical-stage oral selective estrogen receptor degrader (SERD), for use as a monotherapy and in combination with CDK4/6 inhibitors, initially Ibrance (palbociclib), for the treatment of estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-breast cancer.

Company Info

G1 THERAPEUTICS INC

700 Park Offices Drive, Suite 200

RESEARCH TRIANGLE PARK NORTH CAROLINA 27709

P: 19192139835.0

CEO: John E. Bailey Jr.

Employees: 148

Website: https://www.g1therapeutics.com/

GTHX News

News Imagea day ago - G1 TherapeuticsG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Oct. 03, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today...

News Image16 days ago - Market News VideoFirst Week of November 18th Options Trading For G1 Therapeutics (GTHX)News Imagea month ago - G1 TherapeuticsG1 Therapeutics to Participate Virtually in the H.C. Wainwright 24th Annual Global Investment Conference

RESEARCH TRIANGLE PARK, N.C., Sept. 07, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today...

News Imagea month ago - G1 TherapeuticsG1 Therapeutics to Host Virtual R&D Day on September 15, 2022

RESEARCH TRIANGLE PARK, N.C., Sept. 06, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today...

News Imagea month ago - G1 TherapeuticsG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today...

News Image2 months ago - G1 TherapeuticsG1 Therapeutics Provides Second Quarter 2022 Financial Results and Operational Highlights

- Achieved $8.7 Million in Net Revenue from Sales of COSELA® (trilaciclib) in the Second Quarter of 2022 and $10.6 Million in Total Revenue - - Completed...

GTHX Twits

Here you can normally see the latest stock twits on GTHX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example